Point Biopharma Global

Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint

Despite achieving its Phase 3 study's main goal, the results for Point Biopharma's therapy are short of what Novartis radiopharmaceutical Pluvicto achieved in a similarly designed clinical trial. Nevertheless, the data readout should clear the way for Eli Lilly to complete its $1.4 billion acquisition of Point.

By Frank Vinluan

BioPharma, Pharma

Eli Lilly Jumps Into Radiopharmaceuticals via $1.4B Point Biopharma Acquisition

Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate.

By Frank Vinluan

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

Physicians

OmniLife Health’s Clinical Workflow Solution Focuses on Complex Care

OmniLife Health's initial focus with its complex care coordination platform is organ transplant care.

Health Tech

HealthBook+ CEO Shares Vision for How People Can Own Their Health by Leveraging Data and AI

HealthBook+ provides a way for individuals to aggregate and use their personal health information safely and securely to power AI engines that direct people to their next best health action. Importantly, it also gives employers predictive insights to help them provide the most relevant benefits for their employees.